Is SkyePharma PLC A Better Buy Than Shire PLC Or Hikma Pharmaceuticals Plc?

Can upstart SkyePharma PLC (LON:SKP) continue to leap ahead of Shire PLC (LON:SHP) and Hikma Pharmaceuticals Plc (LON:HIK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pharmaceutical stocks SkyePharma (LSE: SKP), Shire (LSE: SHP) (NASDAQ: SHPG.US) and Hikma Pharmaceuticals (LSE: HIK) have risen by an average of 212% over the last two years.

The gains haven’t been equal, though. Investors in SkyePharma can rightfully feel smug, as their company has risen by 370% since June 2013, compared to 104% for Hikma and 165% for Shire.

The only problem is that SkyePharma shares are down by 17% so far in 2015. Is it time to take profits, or can this smaller firm continue to outperform its larger peers?

Going ex-growth?

All three of these firms have been impressive growth buys. Yet there are signs that earnings per share (eps) growth may be slowing at each firm:

Company

2015 eps growth*

2016 eps growth*

Shire

-39%

+17%

Hikma Pharmaceuticals

-9%

+15%

SkyePharma

+125%

+9%

*Reuters consensus forecasts

SkyePharma still has the most promising growth outlook. The firm issued a trading update on Thursday morning confirming that it expected to match full-year guidance.

However, it looks like next year could see SkyePharma’s rapid growth rate slow to quite pedestrian levels.

In a similar vein, both Shire and Hikma are expected to have a tough year in 2015, mainly due to falling profits from established products and exchange rate effects. Although earnings are expected to pick up in 2016, it’s not clear to me whether either company will regain its former momentum.

Key buying signal

We can’t forecast the future, but we can use the valuation of each of these firms to help decide which, if any, are currently an attractive buy.

Company

2015 forecast P/E

2016 forecast P/E

Shire

22.1

18.8

Hikma Pharmaceuticals

21.5

19.0

SkyePharma

15.5

14.2

Based on these forecasts and current expectations for earnings growth, I don’t think that any of these companies are obviously cheap.

Share prices tend to rise and fall when companies exceed, or miss, expectations. These expectations are already high for Shire and Hikma, so there’s a greater risk of disappointment.

I’d be tempted to pick SkyePharma as the pick of the bunch, because its more modest valuation and smaller size leaves more room for outperformance.

The firm’s current valuation reflects the market’s more measured expectations. These should be easier to meet and perhaps beat. SkyePharma’s core new product, flutiform, is still being rolled out globally, and should drive earnings growth for some time to come.

It’s worth commenting that if you ignore exceptional variations, all three of these companies have historically generated an operating profit margin of 20-30%. SkyePharma has been a little less consistent in this department, but I think that its more stable outlook and strong finances should now mean that profitability becomes more consistent.

Today’s best buy?

In today’s trading update, Peter Grant, SkyePharma’s chief executive, said that “further launches and product approvals” were building momentum for the future.

Although this remark could equally have been made by the bosses of Shire and Hikma, both of which I rate as a hold, I believe that SkyePharma’s much more modest valuation provides investors with the opportunity to profit from this growing momentum.

As a result, I’d say that SkyePharma is an attractive buy and well worth holding onto for existing shareholders.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »